▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #505 by analyst upside · 2026-08-13
IRD
Opus Genetics, Inc.
Healthcare · Market Cap $313M · P/E 0x
ANALYST PRICE TARGET
+182.2%
implied upside to consensus target
Current Price $3.76
Consensus Target $10.61
Bull Target $16.0
Bear Target $8.0
Analysts Covering 18
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
15
Hold
0
Sell
0
52-Week Low $1.04
52-Week High $5.81
YTD Return +77.4%
FUNDAMENTALS
Market Cap $313M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.25
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $10M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.04
52-Week High $5.81
Current Price $3.76
Bear Target $8.0
Bull Target $16.0
● Now $3.76 ● Target $10.61
TRADING DATA
Avg Volume 967K
YTD Return +77.4%
Analyst Count 18
Consensus Buy
Upside to Target +182.2%
Last Updated 2026-08-13

ANALYST SUMMARY

Opus Genetics, Inc. (IRD) is currently trading at $3.76 with a Wall Street consensus price target of $10.61, implying potential upside of 182.2% over the next 12 months. 18 analysts currently cover IRD, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $16.0, while the most cautious has a target of $8.0.

IRD operates in the Healthcare sector with a market capitalisation of $313M. The stock is up 77.4% year-to-date and is currently trading near the upper end of its 52-week range of $1.04 – $5.81.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

AGEN +182.6%
Agenus Inc.
$311M · P/E 2.3x · Buy
XFOR +170.4%
X4 Pharmaceuticals, Inc.
$425M · P/E 3.0x · Buy
SABS +206.2%
SAB Biotherapeutics, Inc.
$346M · P/E 15.8x · Buy
ABEO +164.3%
Abeona Therapeutics Inc.
$425M · P/E 7.8x · Buy
QTTB +178.1%
Q32 Bio Inc.
$458M · P/E 4.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for IRD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Chardan Capital - Reiterated
Buy → Buy 2026-06-18 33% win rate (6 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-06-17 31% win rate (48 calls)
BTIG reit
Buy → Buy 2026-06-16 38% win rate (8 calls)
Citizens reit
Market Outperform → Market Outperform 2026-06-15 Building track record
Guggenheim ● Initiated
Buy 2026-06-04 62% win rate (8 calls)
Leerink Partners ● Initiated
Outperform 2026-05-21 29% win rate (7 calls)
Citizens - Reiterated
Market Outperform → Market Outperform 2026-05-13 Building track record
Citizens ● Initiated
Market Outperform 2026-04-28 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
49
out of 100
Coverage depth
22/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →